Immuron Ltd ADR (IMRN) Stock Price, Quote & News

Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9824 5254

Fax: 61 3 9822 7735

Website: www.immuron.com.au

Address:

62 Lygon Street, Level 3 Carlton South, Carlton, Australia

IntiTheSunGod Sep. 11 at 1:16 PM

$IMRN All 10k of my shares are on loan now as cost to borrow remains over 500%. On Robinhood it’s 776%. I waited out the shorting game over at $LASE earlier in the year. I will do it again here for an easy multi bagger

0 · Reply

franzman1974 Sep. 11 at 12:52 PM

$IMRN

0 · Reply

VikaDelic Sep. 11 at 10:47 AM

$IMRN borrow rate now up to 509%… yea nothing to see here 🤣

0 · Reply

VikaDelic Sep. 10 at 6:54 PM

$IMRN they will need to recoup some shares before short interest is logged at the end of the week. Borrow rate over 500% tells you how bad it is for them at this point… even though it will take a bit to publish the updated numbers, they will make all attempts to disguise how bad it got. Obvious accumulation before catalyst (partnering)

0 · Reply

IntiTheSunGod Sep. 10 at 2:52 PM

$IMRN Partnership with Pullan to find clinical licensing deal - I believe they’ve ready found a suitor and this is based on 120M shares traded on 9/4/26, which led to over 700% cost to borrow.

0 · Reply

IntiTheSunGod Sep. 10 at 2:39 PM

$IMRN https://stocksdownunder.com/immuron-asx-imc-proibs-us-launch/

0 · Reply

IntiTheSunGod Sep. 10 at 1:42 PM

$IMRN cost to borrow is sky high over 700% - what happens when there aren’t any shares to borrow or the interest rate to borrow is too high and the company has record sales?

0 · Reply

franzman1974 Sep. 10 at 1:36 PM

$IMRN bla bla bla... garbage

0 · Reply

Zardiw Sep. 10 at 12:53 PM

#DDAmanda alerted on $SNYR before this 51% move. Caught it early again. #DDAmanda Chart Also found early: $NWGL $IMRN $ONCO Find the next one: https://DDAmanda.com

0 · Reply

IntiTheSunGod Sep. 10 at 3:22 AM

$IMRN ctb remains at 776.25% on $HOOD

0 · Reply

Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up

2026-09-04T10:05:25.000Z - 10 days ago

Immuron to launch Proibs in the U.S.

Fri, 04 Sep 2026 06:00:00 -0400 - 10 days ago

Immuron to launch PROIBS® in the United States

2026-08-28T17:06:06.000Z - 16 days ago

Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges

Thu, 16 Jul 2026 06:00:00 -0400 - 2 months ago

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Mon, 06 Jul 2026 06:00:00 -0400 - 2 months ago

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Wed, 22 Apr 2026 09:00:00 -0400 - 4 months ago

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

Fri, 17 Apr 2026 06:00:00 -0400 - 5 months ago

Immuron Double Digit 3Q Sales Growth

Thu, 05 Mar 2026 11:05:00 -0500 - 6 months ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

2026-03-05T11:00:00.000Z - 6 months ago

Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

Thu, 22 Jan 2026 06:00:00 -0500 - 7 months ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Mon, 19 Jan 2026 06:00:00 -0500 - 7 months ago

Immuron Reports Continued Sales Growth

2025-12-10T13:49:49.000Z - 9 months ago

Why Is Immuron Stock (IMRN) Down Today?

2025-12-03T11:53:11.000Z - 9 months ago

Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes

2025-12-03T11:10:43.000Z - 9 months ago

Immuron anounces new DoD award and clinical trial updates

2025-11-05T11:58:49.000Z - 10 months ago

Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529

2025-11-05T11:25:57.000Z - 10 months ago

Immuron announces FDA approval of IND for IMM-529

2025-11-05T11:25:02.000Z - 10 months ago

Immuron: FDA Approves IND Application For IMM-529

Wed, 05 Nov 2025 06:00:00 -0500 - 10 months ago

Immuron IMM-529 IND approved by FDA

Fri, 17 Oct 2025 11:07:00 -0400 - 11 months ago

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

2025-10-13T12:54:51.000Z - 11 months ago

Immuron Announces Rise In Global Revenue For Q1

Mon, 13 Oct 2025 06:00:00 -0400 - 11 months ago

Immuron Q1 FY26 YoY growth

2025-10-08T11:31:48.000Z - 11 months ago

Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment

2025-10-08T10:16:00.000Z - 11 months ago

Why Immuron Is Rising In Pre-market?

2025-10-08T10:05:07.000Z - 11 months ago

Immuron submitts IND application to FDA for clinical development of IMM-529

Wed, 08 Oct 2025 06:00:00 -0400 - 11 months ago

Immuron Submits IMM-529 IND to FDA

2025-10-02T11:26:44.000Z - 11 months ago

Immuron (IMRN) Updates Shareholders on Key Project Developments

2025-10-02T10:20:08.000Z - 11 months ago

Immuron announces projects update

Thu, 02 Oct 2025 06:00:00 -0400 - 11 months ago

Immuron Letter to Shareholders – Projects Update

2025-08-27T09:20:17.000Z - 1 year ago

Immuron enters partnership with InvestorHub

Tue, 26 Aug 2025 22:29:00 -0400 - 1 year ago

Immuron partners with InvestorHub

2025-07-17T10:05:32.000Z - 1 year ago

Immuron says FY25 global sales exceed projection, up 49% over prior year

Thu, 17 Jul 2025 06:00:00 -0400 - 1 year ago

Immuron - FY25 global sales exceed projection, up 49% on prior year

Fri, 30 May 2025 06:00:00 -0400 - 1 year ago

Immuron Letter to Shareholders: Projects Update

2025-04-11T08:55:40.000Z - 1 year ago

Immuron (IMRN) Achieves Record Sales Milestone

Thu, 10 Apr 2025 18:00:00 -0400 - 1 year ago

Immuron Travelan® highest sales in history

2025-03-05T11:06:32.000Z - 1 year ago

Immuron partners with Calmino to distribute ProIBS in Australia, New Zealand

Wed, 05 Mar 2025 06:00:00 -0500 - 1 year ago

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

2025-01-17T11:10:11.000Z - 1 year ago

Immuron reports strong sales growth of Travelan

Fri, 17 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Travelan® continued strong sales growth

2025-01-15T11:05:46.000Z - 1 year ago

Immuron announces research collaboration agreement with Monash University

Wed, 15 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

2025-01-14T11:10:34.000Z - 1 year ago

Immuron announces Travelan clinical trial update

Tue, 14 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Announces Travelan® Clinical Trial Update

Mon, 02 Dec 2024 06:00:00 -0500 - 1 year ago

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Thu, 21 Nov 2024 18:33:00 -0500 - 1 year ago

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Mon, 18 Nov 2024 08:30:00 -0500 - 1 year ago

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Wed, 16 Oct 2024 06:00:00 -0400 - 1 year ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

2024-10-15T10:10:20.000Z - 1 year ago

Immuron reports Q3 sales of Travelan up 13% vs. Q2

Tue, 15 Oct 2024 06:00:00 -0400 - 1 year ago

Immuron Travelan® continued strong sales growth

2024-10-05T09:06:00.000Z - 1 year ago

Market Cap	11.70M
Revenue (ttm)	5.24M
Net Income (ttm)	-2.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-49.81%
Debt to Equity Ratio	0.00

Volume	468,800
Avg Vol	2,613,672
Day's Range	N/A - N/A
Shares Out	8.07M
Stochastic %K	42%
Beta	1.16
Analysts	Strong Buy
Price Target	$5.00